ASTRAZENECA: AIRSUPRA NOW AVAILABLE AS THE FIRST AND ONLY FDA-APPROVED ANTI-INFLAMMATORY RESCUE OPTION FOR ASTHMA
January 23, 2024
January 23, 2024
WILMINGTON, Delaware, Jan. 23 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca announces AIRSUPRA (albuterol/budesonide), is now commercially available in the US by prescription. AIRSUPRA received FDA approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older./1
AIRSUPRA contains a short . . .
AstraZeneca announces AIRSUPRA (albuterol/budesonide), is now commercially available in the US by prescription. AIRSUPRA received FDA approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older./1
AIRSUPRA contains a short . . .